| Literature DB >> 23396020 |
Mohammad Alqahtani1, Thari Alanazi, Salih Binsalih, Naji Aljohani, Mohammed Alshammari, Ali Ashagag, Mohammed Abdullah, Sara Buabbas, Manar Abdulbaqi.
Abstract
BACKGROUND AND OBJECTIVES: There is limited data available on the characteristics of local Saudi patients diagnosed with congestive heart failure (CHF) and on their adherence to guidelines for managing the disease. This study aimed to fill this gap. DESIGN ANDEntities:
Mesh:
Year: 2012 PMID: 23396020 PMCID: PMC6081124 DOI: 10.5144/0256-4947.2012.583
Source DB: PubMed Journal: Ann Saudi Med ISSN: 0256-4947 Impact factor: 1.526
The New York Heart Association Classification System.12
| Class | NYHA Functional Classification |
|---|---|
|
| |
| I | Patients have cardiac disease but without the resulting limitations of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea or anginal pain |
| II | Patients have cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain |
| III | Patients have cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea or anginal pain |
| IV | Patients have cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased |
Patient characteristics (n=392).
| Males | 208 (53.1) |
| Age (years) | 67.8 (12.8) |
| NYHA Class (mean, SD) | 2.7 (0.9) |
| NYHA 1 | 53 (13.6) |
| NYHA2 | 67 (17.1) |
| NYHA 3 | 203 (51.9) |
| NYHA 4 | 68 (17.4) |
| Mortality | 205 (52.3) |
| Hypertension | 333 (84.9) |
| Smokers | 60 (15.3) |
| Hyperlipidemia | 233 (59.4) |
| Diabetes mellitus type 2 | 242 (61.7) |
| Left ventricular dysfunction (EF <55%) | 289 (73.7) |
| Normal ejection fraction (EF ≥55%) | 101 (25.8) |
| Valvular disease | 45 (11.5) |
| Ischemic cardiomyopathy | 268 (68.5) |
| Chronic atrial fibrillation | 103 (26.3) |
| PTCA/CABG | 91 (23.2) |
| Stroke/transient ischemic attack | 89 (22.7) |
Data presented as N (%) or mean (SD). PTCA: percutaneous transluminal coronary angioplasty, CABG: coronary artery bypass graft
Medications taken by study subjects.
| Angiotensin-converting enzyme inhibitors | 175 (45.1) |
| Angiotensin receptor blocker | 135 (34.8) |
| β-blockers | 269 (69.3) |
| Diuretics | 298 (76.8) |
| Spironolactone | 88 (22.7) |
| Statins | 273 (70.7) |
| Nitrates | 52 (17.7) |
| Anti-arrhythmic | 22 (5.7) |
| Digitalis | 55 (14.2) |
| Aspirin | 241 (62.3) |
| Warfarin | 70 (18.1) |
| Plavix | 85 (22.0) |
| CRT, ICD, Combined | 35 (9.0) |
Data are n (%). CRT: cardiac resynchronization therapy, ICD: intracardiac defribrillator.
Metabolic characteristics of subjects.
| Hemoglobin (g%) | 117.3 (23.0) |
| Creatinine (mg/dL) | 150.9 (126.2) |
| Blood urea nitrogen (mmol/L) | 13.3 (9.4) |
| Glucose (mmol/L) | 10.0 (5.5) |
| Total cholesterol (mmol/L) | 3.6 (1.2) |
| HDL-cholesterol (mmol/L) | 1.0 (0.3) |
| LDL-cholesterol (mmol/L) | 2.3 (0.9) |
| Triglycerides (mmol/L) | 1.6 (0.9) |
| Albumin (g/L) | 34.8 (7.0) |
| Potassium (mEq/L) | 4.4 (0.7) |
| Sodium (mEq/L) | 137.4 (32.2) |
Data are mean (SD).
Comparison between subjects with heart failure and reduced ejection fraction versus heart failure and preserved ejection fraction.
| EF <55% | EF ≥55% | ||
|---|---|---|---|
|
| |||
| Hypertension | 245 | 88 | .51 |
| Diabetes mellitus | 173 | 69 | .11 |
| Coronary artery disease | 230 | 59 | < .001 |
| Atrial fibrillation | 67 | 24 | .54 |
| Stroke/transient ischemic attack | 64 | 25 | .38 |
| Dyslipidemia | 175 | 88 | .26 |
| Mortality | 143 | 44 | .14 |
| Angiotensin-converting enzyme inhibitors | 147 | 28 | < .001 |
| β-blockers | 223 | 46 | < .001 |
| Digitalis | 240 | 94 | .001 |
| Spironoloctone | 79 | 9 | < .001 |
| Diuretics | 219 | 79 | .40 |
| Angiotensin receptor blocker | 102 | 33 | .35 |
Figure 1Percentage (%) Adherence to ACC/AHA guidelines in managing CHF patients with reduced EF.